BioInvent International AB

Equities

BINV

SE0015244520

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm Other stock markets 11:29:51 2024-05-17 am EDT			5-day change	1st Jan Change
29.95 ^SEK	+1.53%		+19.32%	+57.96%

May. 14	Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL	CI
May. 03	Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member	CI

BioInvent International AB Appoints Anna Wickenberg as Vice President Clinical Development

January 22, 2015 at 06:30 am EST

BioInvent International AB announced that Anna Wickenberg has been appointed as Vice President Clinical Development, responsible for the clinical development of BioInvent's drug development projects. She will be part of the Management group and reports to the CEO. Most recently, Anna was responsible for the clinical development of new chemical entities in an orphan indication within CNS at Teva.

Latest news about BioInvent International AB

Bioinvent to Present Additional Promising Phase 1/2A Data At EHA 2024 for BI-1206 with rituximab in NHL	May. 14	CI
Bioinvent International AB Resolves to Elect Laura Lassouw-Polman as New Board Member	May. 03	CI
BioInvent Announces Evaluating Attana Technology	Apr. 30	CI
BioInvent International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 24	CI
BioInvent, Merck & Co. Unit Sign Clinical Trial, Supply Deal for Tumor Treatment as Add-On Therapy for Keytruda	Apr. 03	MT
Transcript : BioInvent International AB, 2023 Earnings Call, Feb 22, 2024	Feb. 22
BioInvent International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
BioInvent International AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
BioInvent International AB Presents Positive First Clinical Data on Anti-FcyRIIB Antibody BI-1607	Dec. 05	CI
Bioinvent Enrolls First Patient in Phase 1/2A Clinical Trial with TNFR2 Antibody BI-1910	Dec. 05	CI
BioInvent Presents Positive Data at SITC from Clinical Phase 1/2a Trial of BI-1808 as Single Agent	Nov. 03	CI
BioInvent Presents Preclinical Data at SITC Providing Clear Evidence of the Potential of Anti-TNFR2 Antibody BI-1910	23-10-31	CI
Transcript : BioInvent International AB, Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
BioInvent International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
Global markets live: Nvidia, Chevron, FedEx, Roche, PepsiCo...	23-10-10
Transgene and BioInvent International AB Announces First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA	23-10-10	CI
BioInvent International Enrolls First Patient for Phase 2a Trial of Cancer Therapy	23-09-22	MT
Bioinvent International AB Recruits First Patient in Single Agent Phase 2a Part of its Phase 1/2a Trial of its First-in-Class Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-09-22	CI
BioInvent International AB(OM:BINV) dropped from S&P Global BMI Index	23-09-18	CI
BioInvent International AB Initiates Subcutaneous Arm of Phase 1/2 Trial with BI-1206 in Solid Tumors	23-09-08	CI
BioInvent International To Receive $1 Million Milestone Payment in Exelixis Research Deal	23-09-07	MT
Bioinvent International AB Achieves Research Milestone Event in Its Exclusive Option and License Agreement with Exelixis, Inc	23-09-07	CI
BioInvent International AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-30	CI
BioInvent International AB Reports Strong Interim Safety Data and Early Signs of Efficacy in Phase 1/2a Trial with Anti-TNFR2 Antibody BI-1808 in Advanced Malignancies	23-06-21	CI
BioInvent International AB Announces Abstract Presentation of BI-1206 At the 17th International Conference of Malignant Lymphoma 2023	23-06-13	CI

Chart BioInvent International AB

Duration

Period

More charts

Company Profile

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Companyâs operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Sector

Biotechnology & Medical Research

Calendar

2024-06-01 - American Society of Clinical Oncology Annual Meeting - Abstract Number: 2641

More about the company

Income Statement Evolution

More financial data

Ratings for BioInvent International AB

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

29.5 SEK

Average target price

83 SEK

Spread / Average Target

+181.36%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIOINVENT INTERNATIONAL AB	+57.96%	181M
VERTEX PHARMACEUTICALS INCORPORATED	+9.34%	114B
REGENERON PHARMACEUTICALS, INC.	+11.61%	104B
BIONTECH SE	-13.77%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.24%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.48%	14.28B
SAREPTA THERAPEUTICS, INC.	+35.68%	12.55B

Bio Therapeutic Drugs